Changes in gene expression.

<p>Relative changes in gene expression of irisin-related genes following singular sessions of intense endurance exercise (END) or heavy strength training (STR). Muscle biopsies were sampled 4h post exercise. Data are mean values ± SEM. * = p≤0.05.</p

Plasma concentration of irisin.

<p>Plasma concentration of irisin measured following singular sessions of intense endurance (END) or heavy strength training (STR), or on a control day (CON) without training. Data are mean values ± SEM. The type of intervention had a significant effect on plasma irisin levels (p = 0.022; based on analyses of values from pre, 2h and 6h). There was also an effect of time after exercise (p = 0.007).</p

Lean body mass and exercise induced changes in irisin.

<p>Correlations between proportions of lean body mass and relative changes in plasma irisin following singular sessions of intense endurance exercise (END) or heavy strength training (STR), or on a control day (CON) without training. The X axis represent individual % lean body mass. The Y axis represent individual changes in irisin concentration from baseline to each of the different time points with blood samples. Correlation analyses were performed using Pearson’s method, except of the ones marked ^sp, which were performed using Spearman’s method due to a lack of normal distribution. # = p≤0.05.</p

Subject characteristics.

<p>Mean ± SD.</p><p>Subject characteristics.</p

Predictors of PTX3.

<p>Predictors of PTX3.</p

PTX3 and established markers of disease activity at baseline, 6 weeks and 6 months of treatment.

<p>Values are given in median. IRD, inflammatory rheumatic disease; RA, rheumatoid arthritis; PsA, psoriatic arthritis; AS, ankylosing spondylitis; PTX3, pentraxin 3; WBC, white blood cells; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; PGA, Physicians Global Assessment Score of disease activity; PtGA, Patients' Global Assessment Score of disease activity. X p<0.01 for difference between the evaluation at baseline and at 6 weeks ¥ p<0.01 for difference between the evaluation at 6 weeks and 6 months.</p

Baseline patient characteristics.

<p>Baseline patient characteristics.</p